Repligen Co. (NASDAQ:RGEN) Sees Significant Increase in Short Interest

Repligen Co. (NASDAQ:RGENGet Rating) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 2,780,000 shares, a growth of 21.4% from the April 15th total of 2,290,000 shares. Based on an average trading volume of 519,600 shares, the short-interest ratio is presently 5.4 days. Currently, 5.4% of the company’s stock are sold short.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,000 shares of Repligen stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP raised its position in shares of Repligen by 174.3% in the fourth quarter. First Trust Advisors LP now owns 135,124 shares of the biotechnology company’s stock worth $35,786,000 after acquiring an additional 85,857 shares during the period. Ensign Peak Advisors Inc increased its position in shares of Repligen by 5.6% in the third quarter. Ensign Peak Advisors Inc now owns 63,124 shares of the biotechnology company’s stock valued at $18,242,000 after buying an additional 3,355 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Repligen by 24.9% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 5,480 shares of the biotechnology company’s stock worth $1,451,000 after buying an additional 1,094 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of Repligen by 182.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 28,325 shares of the biotechnology company’s stock valued at $8,186,000 after buying an additional 18,289 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Repligen during the third quarter valued at $816,000. 86.82% of the stock is currently owned by hedge funds and other institutional investors.

Shares of RGEN stock traded down $1.52 on Wednesday, hitting $153.16. The company had a trading volume of 2,627 shares, compared to its average volume of 721,497. Repligen has a twelve month low of $137.21 and a twelve month high of $327.32. The firm has a market cap of $8.34 billion, a P/E ratio of 61.14 and a beta of 0.98. The company has a 50-day moving average price of $166.13 and a 200-day moving average price of $207.72.

Repligen (NASDAQ:RGENGet Rating) last announced its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.20. The company had revenue of $206.40 million during the quarter, compared to the consensus estimate of $185.48 million. Repligen had a return on equity of 11.13% and a net margin of 19.86%. Repligen’s revenue for the quarter was up 44.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 earnings per share. As a group, sell-side analysts predict that Repligen will post 3.1 earnings per share for the current fiscal year.

A number of research firms recently commented on RGEN. Craig Hallum lowered their target price on shares of Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. SVB Leerink lowered their price objective on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, February 18th. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating and set a $190.00 target price on the stock. in a research report on Monday, February 21st. Finally, StockNews.com started coverage on Repligen in a research report on Thursday, March 31st. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $285.57.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.